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and Zong Sheng Guo1*Abstract
Oncolytic viruses (OVs) are tumor-selective, multi-mechanistic antitumor agents. They kill infected cancer and
associated endothelial cells via direct oncolysis, and uninfected cells via tumor vasculature targeting and bystander
effect. Multimodal immunogenic cell death (ICD) together with autophagy often induced by OVs not only presents
potent danger signals to dendritic cells but also efficiently cross-present tumor-associated antigens from cancer
cells to dendritic cells to T cells to induce adaptive antitumor immunity. With this favorable immune backdrop,
genetic engineering of OVs and rational combinations further potentiate OVs as cancer vaccines. OVs armed with
GM-CSF (such as T-VEC and Pexa-Vec) or other immunostimulatory genes, induce potent anti-tumor immunity in
both animal models and human patients. Combination with other immunotherapy regimens improve overall
therapeutic efficacy. Coadministration with a HDAC inhibitor inhibits innate immunity transiently to promote
infection and spread of OVs, and significantly enhances anti-tumor immunity and improves the therapeutic index.
Local administration or OV mediated-expression of ligands for Toll-like receptors can rescue the function of tumor-
infiltrating CD8+ T cells inhibited by the immunosuppressive tumor microenvironment and thus enhances the
antitumor effect. Combination with cyclophosphamide further induces ICD, depletes Treg, and thus potentiates
antitumor immunity. In summary, OVs properly armed or in rational combinations are potent therapeutic cancer
vaccines.
Keywords: Oncolysis, Immunogenic cell death, Autophagy, Antigen, Cross-presentation, Antitumor immunity,
Immunotherapy, Cancer vaccineIntroduction
In the last few years, there is mounting evidence that OVs
are effective in treating cancer in both preclinical models
and clinical trials with human patients [1-3]. The antican-
cer activities of OVs are derived from multimodal cancer
killing mechanisms. The first is the direct oncolysis of can-
cer cells by the virus, which is, in most cases a mixture of
apoptosis, necrosis, pyroptosis and autophagic cell death,
often with one as predominant for a particular OV. The
second is apoptotic and necrotic death of uninfected cells
induced by anti-angiogenesis and anti-vasculature of the
OVs as shown in animals and humans [4-6]. The last is
cytotoxicity to cancer and stromal cells by activated innate
and tumor-specific immune cells [7-9]. The antitumor im-
munity helps eliminate the uninfected cancer cells* Correspondence: GuoZS@upmc.edu
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reproduction in any medium, provided the orin primary and metastatic nodules, and enforce
micrometastases in dormant state.
Cancer vaccines are designed to boost the body’s immune
system to protect itself from carcinogenesis and progression
of cancer. The Food and Drug Administration of the USA
has approved both prophylactic and therapeutic vaccines
for cancer in the last few years. The prophylactic vaccines
are against the hepatitis B virus, which can cause liver can-
cer, and against human papillomavirus types 16 and 18,
which are responsible for about 70 percent of cervical can-
cer cases. These anti-viral vaccines are highly effective in
curbing virus infections and onset of cancer. In contrast,
therapeutic cancer vaccines are difficult to develop and
much less effective. As a benchmark, Provenge, a cancer
vaccine designed to treat advanced prostate cancer, demon-
strated an increase in survival and thus gained approval
from the FDA for use in the treatment of advanced prostate
cancer patients in 2010 [10]. The approval of Provenge has
stimulated interest in development of other therapeutic
cancer vaccines.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cer vaccines over conventional therapies. First, OVs are
tumor-selective, thus in situ cancer vaccines, providing
higher cancer specificity and better safety margin. Sec-
ond, immunogenic/inflammatory types of cell death, in-
cluding recently characterized “immunogenic cell death”
(ICD) of cancer and stromal cells induced by OVs pro-
vides a natural repertoire of tumor-associated antigens
(TAAs) in conjunction with danger signals [damage-asso-
ciated molecular pattern (DAMP) and OV-derived
pathogen-associated molecular pattern (PAMP) mole-
cules, and inflammatory cytokines] [11-13], to elicit anti-
tumor immunity. However, just like other immunothera-
peutic regimens, a number of challenges remain for OVs-
mediated cancer vaccines. For example, the relative ineffi-
ciency of delivering OVs to tumor nodules, selective viral
replication inside tumor nodules and spread to distant
micrometastases limits its overall efficacy. In order to
make up this deficiency, it often requires combinations
with conventional treatments for cytoreduction to de-
crease the tumor burden. Most TAAs are self-antigens
and thus weakly immunogenic. In addition, a highly im-
munosuppressive tumor microenvironment (TME) often
suppresses the activities of tumor-infiltrated lymphocytes
(TILs) generated spontaneously, by adoptive cell transfer
or by active immunization such as cancer vaccines. There-
fore, the balance between tumor growth and the status of
the TME, versus the magnitude and avidity of antitumor
immune response elicited by a therapeutic vaccine in
addition to oncolytic potency by an OV ultimately deter-
mines the therapeutic efficacy by this approach [9,14-17].
In this review, we briefly introduce oncolytic virotherapy
and cancer immunotherapy, then focus on the rationales
and strategies of utilizing replicating OVs as therapeutic
cancer vaccines, and combination strategies that have led
to potent antitumor immunity in preclinical models and
demonstration of the effectiveness of two OVs in clinical
trials.
OVs and cancer immunotherapy
OVs possess the ability to selectively infect and replicate in
cancer and associated endothelial cells and kill these cells
in cancerous tissues while leaving normal tissues un-
harmed [1,3]. Many naturally occurring OVs have a prefer-
ential tropism for tumor and/or associated endothelial
cells. Others are genetically engineered to change their
cellular or organ tropism to cancer. The mechanisms of
tumor targeting by OVs, which include selectivity to can-
cer cells and/or associated endothelial cells with altered
signaling pathways of RB/E2F/p16, p53, PKR, EGFR, Ras,
Wnt, anti-apoptosis, hypoxia conditions, or defects in IFN
and other cellular innate immune signaling pathways have
been reviewed [1,3,18]. The altered signaling pathways fos-
ter favorable cellular environments for specific OVs toreplicate sufficiently in cancer cells and/or associated endo-
thelial cells, leading to direct oncolysis of the infected cells.
Viruses often display specificity for a cell type, tissue or
species, collectively known as viral tropism. Cytokines,
particularly interferons and tumor necrosis factors, play
key roles in dictating the viral tropism [19,20]. Comple-
ment system seems to play certain roles, as shown for
Newcastle disease virus [21]. OVs also displayed species
specificity even though they broaden their tropism to can-
cer cells from non-permissive species to various degrees.
Myxoma virus, a poxvirus previously considered rabbit
specific, can replicate productively in a variety of human
tumor cells [22]. Bovine herpes virus type 1 is a species-
specific virus that fails to induce cytopathic effects in hu-
man normal cells, yet is capable of infecting and killing a
variety of immortalized and transformed human cell types
[23]. However, human Ad can infect murine cancer cells
yet the production of infectious virus progeny is often lim-
ited. One reason is the failure of translation of viral
mRNAs and this could be overcome partially by expres-
sion of L4-100 K in trans [24]. It is important to note that
OVs show aberrant, non-productive infection in non-
native hosts such as mouse cells. In this case, the resulting
mode of cell death can considerably differ from oncolysis
in human cancer cells. As we will discuss later, the mode
of cell death dictates to a large degree the subsequent
antitumor immunity. Consequently, the antitumor immun-
ity determined by studies in immunocompetent animal
models with syngeneic tumors might not be relevant to the
situation in human cancer patients.
OVs mediate multimodal killing of cancer and stromal
cells ranging from direct virus-mediated cytotoxicity
[25-28], cell death due to anti-angiogenesis and vascula-
ture targeting by OVs, to cytotoxic immune effector-
induced cytotoxicity. The types of cell death, as classi-
fied by morphological and ultrastructural changes dur-
ing cell death, are apoptosis, necrosis, and autophagic
cell death. With the exception of apoptosis, all other
types of cell death have been considered to be inflam-
matory and immunogenic. However, recent studies by
investigators working on chemotherapy and radiation
for cancer therapy have led to new concepts, that apop-
totic cell death can be divided into “immunogenic cell
death” (ICD) and “non-immunogenic cell death” (NICD)
[29-31]. Based on this new classification, apoptotic cell
death caused by some OVs are ICD. Together, immuno-
genic apoptosis, necrosis, autophagic cell death and
pyroptosis of cancer and associated endothelial cells caused
by OVs release and present danger signals (DAMPs and
PAMPs as signal 0) and TAAs (as signal 1) to dendritic cells
(DCs) for antitumor and antiviral immune responses.
Immunotherapy has been a bright spot in the field of
novel therapeutics for cancer in the last few years [32-34].
Tumor cells and associated stromal cells such as
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function as antigens including mutated proteins, fusion
proteins, developmentally and tissue-restricted proteins, as
well as tumor-selectively over-expressed proteins, termed
as TAAs [17]. These TAAs are direct targets for most im-
munotherapeutic regimens, either active immunization or
adoptive transfer of activated immune cells [14,33,34]. The
TME, in which cancer cells, stromal cells and infiltrated im-
mune cells, as well as soluble molecules interact with each
other and dictate its properties, is immune tolerangenic or
more likely immunosuppressive [35]. However, the TME
and associated signaling pathways can be manipulated to
activate antitumor immunity in a therapeutic regimen.
Thus, a number of immunotherapeutic strategies are aimed
to disrupt the immune-regulatory circuits that are critical
for maintaining tumor tolerance, such as CTLA-4 and PD-
1, and augment protective antitumor immunity [15,35-37].
OV-induced ICD and autophagy elicit antitumor
immune responses
The cell death can be classified according to morpho-
logic and ultrastructural changes of dying cells, into
apoptosis, necrosis, autophagic cell death, pyroptosis
and a few other types of death [38,39]. As stated, necrosis,
pyroptosis and autophagic cell death are proinflammatory
and immunogenic. Necrosis release DAMPs from dying
cells. Autophagic cell death also releases many DAMPs.
Pyroptosis, triggered by pathogens [40], is highly inflam-
matory. The only exception is apoptosis. Apoptotic cell
death was considered to be non-immunogenic and non-
inflammatory by nature (Table 1). However, recent studies
suggest that, under certain circumstances, apoptosis can
be ICD [29,30,41,42]. ICD involves changes in the com-
position of the cell surface as well as the release of soluble
mediators, occurring in a defined temporal sequence. At
the early phase of immunogenic apoptosis, surface-Table 1 Types of cell death and their immunological consequ
Type of cell death
Apoptosis (type 1 cell death). This is accompanied by a rounding up of the
cell, retraction of pseudopods, reduction of cellular volume, chromatin
condensation, nuclear fragmentation, few or no ultrastructural modifications
of cytoplasmic organelles, and plasma membrane blebbing, but the
integrity of the cell is maintained until the final stages of the process.
Autophagic cell death (ACD; type 2 cell death). Occurs without chromatin
condensation but is accompanied by massive autophagic vacuolization of
the cytoplasm. The term ACD simply describes cell death with autophagy.
Necrosis (type 3 cell death). Characterized by a gain in cell volume,
swelling of organelles and rupture of plasma membrane, and subsequent
loss of intracellular contents, including HMGB1, ATP, etc.
Pyroptosis (or caspase 1-dependent cell death). It is a highly
inflammatory form of cell death mediated by the inflammasome and
caspase-1 activation, and triggered by various pathological stimuli,
such as microbial infection, or stroke, heart attack and cancer.
Secondary necrosis. This is the dissolution of the cell following
apoptosis. Some remaining cellular contents are released.exposed calreticulin (ecto-CRT) and secreted ATP are
crucial DAMPs [43]. While calreticulin (CRT) exposure
on the cell surface prior to apoptosis dictates the immuno-
genicity of cancer cell death [29,30,41,42], ERP57 is a key
protein that controls immunogenicity by controlling CRT
exposure [44,45]. In response to ICD inducers, activation of
endoplasmic reticulum (ER) stress is indispensable to con-
fer the immunogenic character of cancer cell death, because
ER stress can coordinate the danger signaling pathways re-
sponsible for the trafficking of vital DAMPs and subsequent
anti-cancer immune responses. Other pathways such as au-
tophagy (discussed later) have the ability to influence dan-
ger signaling and thus antitumor immune response [46]. At
later stages, other DAMPs such as HMGB1 are released
from dying cancer cells and secreted from activated infil-
trated immune cells [13,43,47-49]. Kroemer, Zitvogel and
others believed that ICD constitutes a prominent pathway
for the activation of the immune system against cancer,
which in turn determines the long-term success of antican-
cer therapies [43,48,50]. The immunogenic characteristics
of ICD are mainly mediated by DAMPs that include ecto-
CRT, secreted ATP and released HMGB1. Thus, the revised
concept ICD would include not only immunogenic apop-
tosis, but also necrosis, pyroptosis, and autophagic cell
death [29,30,42,43,46,51-53].
Cancer cell death induced by OVs is mostly immuno-
genic (Table 2). For example, an oncolytic hTERT-Ad in-
duced autophagic cell death in tumor cells and in
subcutaneous gliomas, which is immunogenic [54]. Mea-
sles virus causes ICD in human melanoma cells [55].
Interestingly, a significant portion of the in vivo tumor
killing activity by OVs, e.g., vesicular stomatitis virus
(VSV) and vaccinia virus (VV), is caused by indirect kill-
ing of uninfected tumor cells [4]. OVs also target endo-
thelial cells and tumor vasculature, leading to infection
and lysis of endothelial cells, and more necrotic death ofence
Immunogenicity
Some forms of apoptosis are non-immunologic, while others are
immunogenic. The pre-apoptotic surface exposure of CRT and
HSP70/HSP90 may have a profound impact on the immune response. In
addition, the release of HMGB1 during late apoptosis promotes antigen
processing by DCs and hence contributes to cytotoxic T-cell activation.
High. It may release DAMPs (HMGB1, ATP, and others) and elicit
substantial inflammation.
High. This causes release of DAMPs and elicits substantial inflammation
and affects local environment.
High. It is a highly inflammatory form of cell death due to cytokine
release and escape of cytoplasmic contents (DAMPs). However, some
pathogens encode immunosuppressive proteins.
High. It is quite immunogenic due to necrosis occurring in
apoptotic cells at the late stage.
Table 2 OVs induce ICD and/or promote antitumor immunity in animal models or human patients (*)
Virus Modifications ICD and DAMPs (in vitro) Antitumor Immunity (in vivo) Reference
Ad
hTERT-Ad E1a gene driven by hTERT
promoter
Immunogenic apoptosis hTERT-Ad and bortezmib (proteasome inhibition) leads to
potent antitumor immunity
[65]
Ad5/3-D24-GMCSF Ad3 fiber E1a-deleted
(RB-selective) GM-CSF +
Enhanced autophagy; ecto- CRT;
released ATP and HMGB1
Tumor-specific T cell responses and antitumor efficacy in
some patients [clinical trial]
[62]
HSV
G207 R34.5-; ICP6- NA Systemic antitumor immunity (CD8+ T cells) [66]
HSV-1716 ICP 34.5 gene mutant Induction of IFN-γ, CXCL9 and
CXCL10
Intratumoral injection increased NK and CD8+ T cells [67]
T-VEC ICP47-γ34.5 - GM-CSF + Necrosis/apoptosis (in vivo) Antigen-specific T cell responses and decreases in Treg, Ts,
and MDSC in human melanoma patients [clinical trials]
[68,69]
HSV-2 ΔPK mutant ICP10 PK domain deleted Apoptosis/Pyroptosis Dominant induction of CD4+ Th1 cells [70]
Poxvirus
vSP Spi-1/spi-2- Necrosis/apoptosis HMGB1 release NA [58]
vvDD tk-/vgf- Necrosis/HMGB1 and ATP release CD11b + cells and CD11b+Ly6G+ cells (DCs and Neutrophils) [71]
Pexa-Vec tk-GM-CSF+ NA Antiviral CTL and antibodies against TAAs in Human
HCC patients [clinical trial]
[72]
Arbovirus
VSV-GFP (Indiana serotype) Marker gene GFP Induction of IL-28 by virally activated
innate immune cells in the TME
IL-28 sensitize cancer cells to NK cell recognition and killing [73]
VSVgm-icv oncolytic vaccine
plateform
Deletion in The M protein at
position 51; VSV-GM-CSF+
NA The antitumor immunity is robust enough to control established tumor.
Tumor is infiltrated by a large number of IFNγ-producing T and NK cells
[74]
Paramyxovirus
MV-eGFP (Edmonston strain) Marker gene EGFP Released inflammatory cytokines
and chemokines; IL-6 and HMGB1
Enhance innate antitumor and melanoma-specific adaptive immunity
(in vitro)
[55]
MV vaccine-infected tumor cells Marker gene EGFP ICD; apoptotic cells phagocytosed
by DCs
Allowing DC to mature, produce high level of IFN-α, and cross-present
TAAs and production of tumor-specific CD8 T cells
[75,76]
*Notes:
(1). data for T-VEC and Pexa-Vec are from human patients;
(2). NA, not assessed.
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[4-6,56,57]. As for the release of DAMPs from dying
cancer cells, we first reported that cancer cells infected
by an oncolytic virus, led to necrotic/apoptotic death
pathways and HMGB1 was released into the extracellular
milieu [58]. As it turns out, HMGB1 release is a universal
phenomenon for OVs, as shown in cancer cells infected
with an Ad [59], a measles virus [55], an HSV-2 [60], and
a coxsackievirus B3 [61]. Extracellular ATP is another po-
tent danger signal released from OV-infected cancer cells
[59,61,62]. Together, tumor cell death and ATP release
may prime DC and lead to efficient antitumor immunity
[63]. Finally, activated innate immune cells and elicited
adaptive anti-cancer immunity as well as inflammatory cy-
tokines kill additional cancer cells and stromal cells, lead-
ing to release of DAMPs such as HMGB1 [64]. In
summary, these studies strengthen the notion that OVs in-
duce immunogenic types of cell death and present/release
a number of danger signals, and TAAs to DCs andFigure 1 ICD of cancer cells induced by OVs leads to antitumor immu
tumor tissue and selectively replicates in tumor or/and stromal cells. This le
the cell surface and later release of danger signals from necrotic cells. Apop
presented along with MHC complex and costimulatory molecules. The rele
cross-presented to naive T cells. This process can be further enhanced at d
strategy). The resulting cytotoxic immune response against tumor and asso
complete eradication of tumor mass. Additional immunotherapies targeting
this antitumor immune response.immune system to elicit antitumor immune responses
(Figure 1 and Table 2).
Autophagy plays roles in both innate and adaptive im-
munity [13,77,78], and it is a tightly regulated mechanism
that mediates sequestration, degradation, and recycling of
cellular proteins, organelles, and pathogens. OVs such as
Ad [54,79-81], HSV [70,82,83], reovirus [84-86], influenza
virus [87], VSV and encephalomyocarditis virus [88] in-
duce autophagy in cancer cells. Autophagy enhances
tumor immunogenicity by two mechanisms. First, dying
cells with autophagy (autophagic cell death) selectively re-
lease DAMPs such as HMGB1[89], ATP [52,90], and uric
acid [91]. Second, autophagy promotes antigen cross-
presentation from cancer cells to DCs and then T cells.
Autophagy stimulates antigen processing not only for
MHC class II, but also for MHC class I pathway [92,93],
as shown for endogenous viral antigens during HSV-1 in-
fection [82], and for cross-presentation of TAAs from un-
infected cancer cells [94], and influenza A virus-infectednity. An OV, delivered either intratumorally or systemically, reaches to
ads to induction of death of these cells, presenting “eat me” signals on
totic bodies are engulfed by APC, and TAAs are processed and
ased DAMPs (and PAMPs) activate and mature DCs, and TAAs are
ifferent steps by other immunomodulatory agents (in a combination
ciated stromal cells, involving CD4+ and CD8+ T cells, may help in
DCs, T cells, and the immunosuppressive TME can further enhance
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presentation almost completely, whereas induction of au-
tophagy dramatically enhanced the cross-presentation of
TAAs. Interestingly, purified autophagosomes could func-
tion as efficient antigen carriers for cross-presentation.
These studies demonstrated that autophagy within the
antigen donor cells facilitates antigen cross-priming to
generate TAA-specific or virus-specific CD8+ T cells
[75,94,96], which could be further explored as a new strat-
egy to enhance OV-mediated antitumor effects in the fu-
ture [97].
In summary, ICD and autophagy triggered by a num-
ber of OVs provide a highly favorable backdrop for the
immune system to respond and generate a potent adap-
tive antitumor immunity (Table 2).
Oncolytic viruses as therapeutic cancer vaccines
OVs have been explored as therapeutic cancer vaccines
for quite a few decades. Pioneering work done by
Lindenmann and Klein in 1967 demonstrated that viral
oncolysis of tumor cells by influenza virus increases im-
munogenicity of tumor cell antigens [98]. A few decades
later, Martuza, Toda and others demonstrated that a gen-
etically engineered oncolytic HSV G207 functions as an in
situ cancer vaccine for induction of specific anti-tumor
immunity in CT26 colon cancer model [66]. When this
virus is armed with IL-12, the virally expressed IL-12 can
work with the OV synergistically to elicit local and sys-
temic anti-tumor immunity [99].
In order to make OVs better therapeutic cancer vaccines,
investigators have recently come up with a number of gen-
etically engineered and armed OVs and combination strat-
egies with other anti-cancer agents that may work either
additively or synergistically to produce potent oncolysis
and antitumor immunity. A number of studies lead us to
note two interesting findings. One is that adaptive antiviral
immunity may not be all bad. In fact, adaptive antiviral im-
munity contributes to oncolytic virotherapy by an oncolytic
HSV [100], even though it may not be the case for all OVs.
The second is that selectivity of oncolytic viral replication
may reduce antiviral immunity and toxicity, but it does not
improve antitumor immunity [101]. The therapeutic effi-
cacy of an OV is a delicate balance of forces, between ef-
fective viral replication and oncolysis, viral clearance by
antiviral immunity, and antitumor immunity and factors
promoting tumor growth [102,103]. Thus, any combin-
ation with immunotherapy should take antiviral immunity
into account.
A. Genetic modifications of OVs for enhanced immune
responses
Genetic modifications of OVs aim to relieve the inhib-
ition of immune responses by the OVs with deletion ofviral immune evasion genes, and to enhance antitumor
immune responses by inserting immune-enhancing
transgenes into the OV vectors. Clearly, no-armed OVs
can elicit antitumor immunity in certain tumor models,
as demonstrated with HSV-1 G207, H-1716, MV-EGFP
and Coxackievirus B3 [55,61,66,67,104]. However, many
studies have shown that immunological effects can vary
depending on a number of factors including tumor im-
munogenicity, stage of the tumor and specifics of the
particular OV used. To gain better immunological ef-
fects, a number of steps in immune response and mul-
tiple cell types can be targeted by armed OVs or by
combination strategies. We will discuss some recent
studies to illustrate these points.
(1) Modulating the innate immunity
Toll-like receptors (TLRs) are a family of pattern rec-
ognition receptors that recognize PAMPs and DAMPs,
and trigger the activation and maturation of DCs. As
an example, TLR9 responds to viral dsDNA by recog-
nizing unmethylated CpG sequences; thus CpG rich
oligodeoxynucleotides have been used as vaccine adju-
vants. Along the same logic, oncolytic DNA viruses
enriched with CpG motifs are believed to be stronger
immunogens. Raykov et al. have tested this idea in a
rat lung hepatoma metastasis model by using autolo-
gous tumor cells that were infected with CpG enriched
parvovirus and then irradiated. They showed a signifi-
cant reduction in metastatic rate compared with con-
trols [105]. Cerullo et al. have also tested the anti-
tumor effects of an oncolytic Ad enriched with CpG
motifs (Ad5D24-CpG) in cancer models [106]. In a
syngeneic mouse model with B16-OVA melanoma,
Ad5D24-CpG significantly improved tumor control,
associated a significant increase in tumor and spleen
anti-OVA specific T-cells and a decrease in both num-
ber and activation of MDSCs in the tumor.
(2) Enhancing the cross-presentation and priming of
TAAs
Heat shock proteins (HSPs) are a family of proteins that
act as molecular chaperones and can be induced or re-
leased during cellular stress or necrosis. Once they are ex-
posed on the cell surface or released, they become active
DAMPs. Due to their mechanistic abilities to catalyze the
folding of proteins and their intracellular translocation,
HSPs can bind potential antigens at a necrotic scene and
deliver them to a variety of antigen presenting cells [107].
Oncolytic Ads expressing several HSPs, including HSP70,
HSP90 and HSF1, a heat shock transcription factor, have
been constructed and investigated in tumor models. In-
deed, they can function as oncolytic cancer vaccines and
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CD8+ T cell response in syngeneic melanoma, colorectal
and prostate cancer models in immunocompetent mice
[108,109]. In fact, an HSP70-overexpressing oncolytic Ad
has been tested in a phase I clinical trial [110].
As we have discussed earlier, autophagy induced in can-
cer cells has been shown to promote cross-presentation of
TAAs.
(3) Viruses engineered to express cytokines,
chemokines and co-stimulatory molecules
Many OVs expressing cytokines (such as IL-2, IL-12,
IL-18); chemokines (such as CCL5), or costimulatory
molecules (such as B7.1 and CD40L) have been studied
and some exciting antitumor immunity and therapeutic
results have been documented in animal models and in
human cancer patients. Due to space limit, we will focus
on the GM-CSF armed OVs in this section.
Viruses have evolved with genes to suppress the im-
mune system in order to survive and gain maximum
replication in the hosts [111]. In the context of OVs,
they may play yin-yang roles. On one hand, they may in-
crease viral persistence in the tumor leading to better
oncolysis; while on the other hand, they may inhibit the
immune response to both the virus and cancer, and thus
reduce the potency of antitumor immunity. The balan-
cing act between the two is not only a science, but also
an art [102,112].
Talimogene laherparevec (T-VEC; formerly JS1/ICP34.5-/
ICP47-/GM-CSF or OncoVex), represents a good develop-
ment to realize the potential as an oncolytic vaccine [113].
First, the authors started to build oHSV-1 from a more po-
tent oncolytic strain JS1 instead of a regular laboratory
strain. Then the authors made a number of mutations of
viral genes based on previous findings. Deletion of the
ICP34.5 gene would result in enhanced tumor cell killing.
Mutation in ICP47 serves two functions. One is to increase
the expression of the HSV US11 gene, which enhances rep-
lication of HSV ICP34.5 mutants in tumors. As ICP47 also
functions to block antigen processing in HSV infected cells,
this mutation was also anticipated to improve the immune
stimulating properties of the virus. Finally, in order to pro-
vide viruses with maximum immune stimulating properties,
the human GM-CSF-encoding gene was inserted into the
JS1/34.5-/47- backbone. The data collected at the time indi-
cated that the resulting virus T-VEC acts as a powerful
oncolytic agent. The continued work in multiple clinical tri-
als confirmed and extended the original findings.
Genetically engineered vaccinia virus (VV) is another
good example. The deletion of viral genes encoding thymi-
dine kinase (tk) and vaccinia growth factor (vgf) makes it a
highly tumor-selective one, called vvDD [114]. These mu-
tations restrict virus replication to cells that overexpressE2F (positively regulate cellular TK expression) and have
constitutively activated epithelial growth factor receptor
pathway. When it is armed with GM-CSF gene, its
antitumor immunity and cytotoxicity were further en-
hanced [115].
GM-CSF mediates antitumor effects by recruiting NK
cells and by induction of tumor antigen-specific cytotoxic
T cells through the action of APCs. Some of most promis-
ing OVs are Ad, HSV or VV armed with the human GM-
CSF gene. All three have been tested in multiple clinical
trials. One of the Ad versions, Ad5-D24-GMCSF, induces
antitumor immunity in cancer patients. Of the 16 patients
evaluable, two had complete response, and 5 stable disease
[116]. Another version, a serotype 5/3 chimeric Ad ex-
pressing GM-CSF, has achieved similar immune and clin-
ical responses in cancer patients [117].
The HSV version is T-VEC. In animal models, this virus
acts as a powerful agent with enhanced oncolytic, immune
stimulating, and anti-tumor properties [113]. In a phase I
trial, the virus was generally well tolerated. Virus replica-
tion, local reactions, GM-CSF expression, and HSV
antigen-associated tumor necrosis were observed. After
treatment, most patient biopsies contained residual tumor
of which 14 showed tumor necrosis or apoptosis [68]. In a
phase II trial, patients’ unresectable metastatic melanomas
were treated with multiple intratumoral injections of the
virus, then clinical responses, survival and safety were
monitored. The overall response rate by RECIST was 26%,
with complete response in 8 out of 50 patients [118]. Dir-
ect injection of this virus induced local and systemic
antigen-specific T cell responses and decreased CD4
+FoxP3+ regulatory T cells (Treg), CD8+FoxP3+ suppressor
T cells, and myeloid-derived suppressive cells (MDSC) in
patients exhibiting therapeutic responses [69]. T-VEC has
an approximately 30% response rate against systemic dis-
ease, following local injection into accessible tumors. A
pivotal phase III trial for T-VEC has just been completed
in melanoma, and a phase III trial in head and neck cancer
is also underway [119].
The main findings of the phase III trial were presented
orally at the 2013 American Society of Clinical Oncology
Annual Meeting (Abstract no. LBA9008) [120]. In the
OPTiM trial, 436 patients with unresectable stage IIIB-IV
melanoma were randomized 2:1 to receive either T-VEC
injected into the lesions directly or by ultrasound guid-
ance, or GM-CSF administered subcutaneously. There
were 295 patients in the T-VEC group and 141 partici-
pants in the GM-CSF arm. The overall durable response
rate (DRR) was 16.3% for patients who took T-VEC, com-
pared with 2.1% among participants who received just
GM-CSF. The objective overall response (ORR) rate was
26.4% among the T-VEC group, including 10.8% with a
complete response, compared with an ORR of 5.7% and a
complete response of 0.7% in the GM-CSF group. This is
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OV immunotherapy.
Pexa-Vec (pexastimogene devacirepvec; JX-594; TG6006)
is an oncolytic poxvirus armed with the GM-CSF gene and
it has undergone multiple phase I/II clinical trials and
obtained exciting clinical responses in liver cancer patients
[5,72]. Viral replication and expression of GM-CSF and in-
duction of antitumor immunity were all detected. Interest-
ingly, survival duration of patients was significantly related
to viral dosage, with median survival of 14.1 months com-
pared to 6.7 months on the high and low dose, respectively
[72]. In a related study, Pexa-Vec has been shown to induce
antibody-mediated complement-dependent cancer cell
lysis in humans. The authors have identified about a
dozen of TAAs using serological expression cloning
approach [121].
B. Combination with other immunotherapy regimens
As a form of immunotherapy [7-9], OVs in combination
with other immunotherapy regimens would make sense if
they function additively or synergistically to exert potent
and sustained antitumor immunity. Investigators have
combined OVs with DC-mediated active immunization,
adoptive T cell transfer, or other immune-modulators to
regulate other immune components in order to generate
potent antitumor immunity and improve overall thera-
peutic efficacy.
OVs and DC-mediated cancer vaccines can be com-
bined to improve the efficacy. A recent study has
showed that intratumoral OV-induced inflammation is a
precondition for effective antitumor DC vaccination in
mice [122]. This regimen combining tumor-targeted DC
vaccine with ongoing OV-induced tumor inflammation
elicited potent antitumoral CD8+ T cell responses and
marked tumor regression and successful eradication of
pre-established lung colonies, a model for tumor metas-
tases. One unexpected finding has been that depletion of
Tregs abrogated antitumor cytotoxicity. As such, Tregs
are essential for the therapeutic success of multimodal
and temporally fine-adjusted vaccination strategies.
These results highlight tumor-targeting OVs as attractive
tools for eliciting effective antitumor responses upon DC
vaccination [122].
CD8+ T cells are critical for the efficacy of VSV
virotherapy, and yet these cytotoxic T cells are induced
against both virally encoded and tumor-associated
immunodominant epitopes [123]. Vile group and others
have tested various immune interventions to increase
the frequency/activity of activated antitumoral T cells in
the context of OVs. Treg depletion had a negative thera-
peutic effect because it relieved suppression of the anti-
viral immune response, leading to early viral clearance.
In contrast, increasing the circulating levels of tumorantigen–specific T cells using adoptive T cell transfer
therapy, in combination with intratumoral virotherapy,
generated significantly improved therapy over either
adoptive therapy or virotherapy alone [123]. In addition,
incorporation of a TAA within an OV increased the
levels of activation of naïve T cells against the antigen,
which translated into increased therapeutic efficacy
[123-125]. Therefore, these studies have demonstrated
that combination strategies that enhance immune acti-
vation against TAAs can be integrated to enhance the
efficacy of virotherapy [123-125].
A number of studies have utilized a heterogeneous
“prime-boost” regimen in oncolytic immunotherapy. VSV
engineered to express chicken ovalbumin (OVA) could ef-
ficiently treat mice bearing B16 melanomas expressing
OVA as a model tumor antigen [123,126]. Mice treated
with VSVova developed potent anti-ova immunity and
many of their B16-ova tumors completely regressed. In
another study, a similar regimen using Semliki Forest virus
(SFV) followed by VV, or vice versa, leads to enhanced
antitumor effect against a murine ovarian cancer model
[127]. Infection with SFV-OVA followed with VV-OVA
leads to enhanced antitumor effects through a combin-
ation of viral oncolysis and antigen-specific immunity.
The more clinically relevant strategy has been to develop
OVs that express self-tumor antigens and utilize syngeneic
tumor models with self-tumor antigens. This is much
more challenging, yet investigators have come up with in-
novative approaches. One strategy was to use replicating
OVs to boost antitumor immunity primed by a
nonreplicating Ad-based vaccine [128,129]. Bridle and
colleagues took a heterologous “prime boost” approach
using non-replicating Ad expressing self-antigen hDCT
(Ad-hDCT) as prime intramuscularly, then boosted
with replicating VSV-hDCT by intravenous administra-
tion in a metastatic B16 melanoma model. The im-
munological results are very intriguing but consistent
with other prime-boost regimens. While VSV-hDCT
treatment alone elicited a strong T-cell response to-
wards viral antigens, the prime boost regimen com-
pletely polarized the adaptive immune response towards
the hDCT tumor antigen. Using such a prime-boost
regimen, a large percentage of mice were cured of
tumors.
T and NK cells express several members of the TNF
receptor (TNFR) family specialized in delivering a
costimulatory signal. Engagement of these receptors is
typically associated with proliferation, elevated effector
functions, resistance to apoptosis, and differentiation
into memory cells. Therefore, agonist monoclonal anti-
bodies (mAb) against these molecules have been used to
stimulate antitumor T and NK cells in cancer therapy
settings [130]. It makes sense to combine an OV with
such a mAb for therapeutic purpose. Combining an OV
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costimulatory molecule 4-1BB showed improved thera-
peutic outcomes [71]. Combination of an OV with an
immunomodulatory mAb that blocks T-cell checkpoint
blockade receptors such as CTLA4 has also generated
promising results [131].
To overcome the heterogeneity nature of tumor, a group
of investigators have combined complementary OVs to at-
tack cancers in distinct ways to improve therapeutic out-
come [132]. Two genetically distinct viruses, VSV and VV,
were used to eliminate the risk of recombination. They
found that VV synergistically enhanced VSV antitumor ac-
tivity, dependent in large part on the activity of the VV
B18R protein [132]. Recently, another combination of two
OVs applied at multiple low doses to tumor models of the
Syrian hamster as an immune-competent model enhance
antitumor efficacy through the induction of tumor-specific
immunity and circumvention or mitigation of antiviral im-
mune responses [133].
In most cases, combinations with other immunother-
apy regimens have generated enhanced antitumor im-
munity and better therapeutic outcomes. However, some
of these studies lead to some unexpected conclusions in
the context of OVs. First, adaptive antiviral immunity
contributes to oncolytic virotherapy in the context of
oHSV [100], but high levels of VSV-associated immuno-
genicity distracted immune response away from priming
for tumor-specific T cells [134]. Second, two studies
showed that Treg cells are needed for optimal therapeutic
results, due to either prevention of early viral clearance or
due to the compensatory induction of MDSCs in Treg-
depleted and thus vigorously inflamed tumors which pre-
vent oncolysis-assisted DC vaccination [122,123]. Third, in
prime-boost strategies using two different OVs, the im-
munological outcomes depend upon the order of vaccin-
ation – Ad followed by VV was not only better than either
virus alone but better than VV followed by Ad [133]. This
is not too surprising as similar observations have been
made previously with classic replication-deficient viral
vectors. However, this means that investigators will need
to assess their scheduling carefully in all combination re-
gimes with OVs.
C. Modulation of the TME to promote viral replication
and antitumor immunity
The TME can be modulated not only to promote OV
viral replication and oncolysis, but also the activation,
persistence and activities of antitumor immune cells. We
will discuss only a few such strategies that have been ap-
plied to OV regimens. Innate immune cell recruitment
and activation have been shown to be deleterious to the
efficacy of OVs [135-138]. As an example, NK cells im-
pede glioblastoma virotherapy through NKp30 andNKp46 natural cytotoxicity receptors [139]. One major
trigger for the activation of innate immune cells is the
interferon (IFN) response induced by viral infection.
Quite surprisingly, one class of small molecules that
inhibit the IFN responses is the inhibitors of histone
deacetylases (HDACi) [140,141]. HDACs can influence
epigenetic modifications of histones and chromatin, and
a number of other cellular regulatory proteins, leading
to inhibition of the cellular antiviral response. In one
study, the authors showed that two HDACi, MS-275 and
vorinostat, markedly enhance the infection and spread of
VSV and VV in cancer cells and primary human tumor
tissue explants in vitro, and in multiple animal models.
The authors found that reduced cellular IFN responses
and enhanced virus-induced apoptosis may explain the
increased viral replication and oncolytic activity [142]. It
has been shown that HDACi valproic acid (VPA) aug-
mented antitumor efficacy of oncolytic HSVs [143]. VPA
lessens NK cell action against OV-infected glioblastoma
cells by inhibition of STAT5/T-BET signaling and gener-
ation of IFN-γ [144]. When administered prior to HSV
inoculation in an orthotopic glioblastoma mouse model,
VPA resulted in a reduced recruitment of NK and mac-
rophages into tumor-bearing brains at early time post-
HSV infection. Interestingly, the recruitment of these
cells rebound robustly at a later time point. The authors
corroborate these findings in vitro by demonstrating that
VPA reduces NK cell-mediated cytotoxicity and produc-
tion of gamma interferon. VPA has a profound suppressive
effect on human NK cells by inhibiting NK cell cytotox-
icity via downregulation of cytotoxic proteins granzyme B
and perforin. In addition, suppression of gamma IFN
(IFN-γ) production was associated with decreased STAT5
phosphorylation and dampened T-BET expression. These
results demonstrate that HSV virotherapy of glioblastoma
is limited partially by an antiviral NK cell response, which
can be modulated by VPA or other agents to enhance can-
cer virotherapy [139].
A recent study revealed an unexpected property of
HDACi on adaptive immunity [145]. A class I-specific
HDAC inhibitor, MS-275, induced lymphopenia which
led to selective depletion of bystander lymphocytes and
regulatory T cells while allowing expansion of antigen-
specific secondary responses. Coadministration of vac-
cine (oncolytic VSV) with the drug during the boosting
phase focuses the immune response on the tumor by
suppressing the primary immune response against the
vaccine vector and enhancing the secondary response
against the tumor antigen. Evidence suggests that MS-
275 can orchestrate a complex array of effects that
synergize immunotherapy and viral oncolysis. Overall,
MS-275 enhanced efficacy, suppressed autoimmunity
and thus improved the therapeutic index [145]. In
addition, it is tempting to point out that such as HDACi
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hance the immunogenicity of tumor cells by upregulation
of TAAs [146,147] , and HMC class I antigens and antigen
presentation machinery [148,149], and thus enhance can-
cer immunotherapy [146].
The TME is characterized as chronic indolent inflam-
mation in which the effector function of tumor-
infiltrating lymphocytes (TILs) is severely impaired.
This TME makes the effector cells generated by cancer
vaccines malfunctional and impotent. Recent studies
have shown that costimulation with TLR ligands may
greatly enhance the efficacy of immunotherapy includ-
ing cancer vaccines [150]. Injection of oncolytic VSV
leads to tumor regression in established B16ova melan-
oma model. This effect is in part due to the induction of
innate immunity against the viral infection that is medi-
ated by MyD88- and type III IFN-, but not TLR4-, sig-
naling pathway [151]. Strikingly, intratumoral injection
of lipopolysaccharide (LPS), a TLR-4 agonist, leads to
activation of different innate immune pathways and sig-
nificantly enhances the local oncolytic therapy by VSV.
This antitumor activity is further enhanced by co-
recruiting a potent antitumor, adaptive T-cell response
by using a VSV engineered to express ova, the artificial
tumor antigen, in combination with LPS [152]. How-
ever, this study also highlights unforeseen dangers of
combination therapies in which an immunotherapy may
systemically sensitize the host (potentially a humanA
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systemic delivery of an OV.
The effector function of CD8+ TILs could be rescued
by converting the chronic inflammation milieu to acute
inflammation within tumors. Injection of TLR3/9 ligands
(polyI:C/CpG) into a tumor during the effector phase of
lentivector (lv) immunization effectively rescued the
function of lv-activated CD8+ TILs and decreased the
percentage of Treg within the tumor, resulting in a
marked improvement in the antitumor efficacy of the
immunization [153]. We provided a working mechanism
by showing that rescue of the effector function is most
likely dependent on production of type-1 IFN in the
tumor that can mature and activate tumor-infiltrating
DCs. It is worth noting that many OVs or their products
can be recognized as PAMPs by TLRs or other pattern
recognition receptors (PRRs) expressed by DCs, thus
stimulating DCs [154]. For example, oncolytic parvo-
virus H-1 activates DCs partially through TLR3 and
TLR9 [155]. Reovirus can escape the endosomes of DC
and viral dsRNA triggers non-TLR3 receptor (other PRR
receptor) to induce IFN-γ production, and prime adap-
tive antitumor immunity [156]. Based on these studies,
we have presented a model how TLR ligands rescue the
immunological function of the TILs (Figure 2). In this
model, type I IFN, produced via TLR-TLR ligand signal-
ing and activation of the gene, plays some key roles in
reactivating tumor-infiltrating DCs (TIDCs), whichctivation
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for TLRs.
D. Combination with cyclophosphamide for enhanced
antitumor immunity.
The immune system makes a crucial contribution to the
antitumor effects of conventional chemotherapy- and
radiotherapy-based cancer regimens [157]. Cyclophospha-
mide (CPA) is an alkylating agent and a classic chemothera-
peutic compound. It induces genotoxic stress, apoptosis
and/or cell cycle arrest. Recent studies indicate that it can
enhance viral replication of OVs and adaptive antitumor
immunity in vivo, thus resulting in better efficacy. CPA
functions to promote oncolytic virotherapy mainly via two
mechanisms. (1). CPA enhances viral replication by sup-
pressing antiviral innate immunity. Chiocca and associates
have first applied CPA in combination with oHSV
virotherapy based on the rationale that CPA would reduce
antiviral immunity and thus augment viral replication to
enhance oHSV efficacy [135-137,158]. They discovered that
pretreatment with a single dose of CPA could enhance both
the level and duration of viral replication of HSV within
treated tumors [137,158]. Similar enhancement was also
reported for oncolytic Ad [159]. The CPA-enhanced viral
replication is well correlated to the significantly enhanced
antitumor activities [137,158,160]. Nevertheless, it is worth
noting that not all combinations of an OV with CPA will
work. In fact, VSV-induced immune suppressor cells gener-
ate antagonism between intratumoral OV and CPA [161].
(2). CPA enhances adaptive antitumor immunity induced
by OVs. This is most likely through selective depletion and
inhibition of Treg cells by low dose of CPA [162-164]. CPA
pretreatment followed with virotherapy leads to signifi-
cantly enhanced antitumor immunity in tumor models of
immunocompetent mice, as demonstrated with oncolytic
HSV [160], Ad expressing gp96 [165], and VV expressing
HPV E7 [166]. In addition, CPA can enhance antitumor ac-
tivity of adoptively transferred immune cells through the in-
duction of “cytokine storms” [167]. In the last few years,
CPA in combination with OV has been tested in human
cancer patients. Oncolytic Ad given together with metro-
nomic CP increased cytotoxic T cells and induced Th1 type
immunity on a systemic level in most cancer patients tested
[62,168]. In summary, CPA has emerged as a clinically feas-
ible agent that can suppress Tregs and allow more effective
induction of antitumor responses , in the settings of cancer
vaccines and other immunotherapy strategies [169].
Conclusions
In the capacity of cancer vaccines, OVs exert two of the
most important functions: (1). They kill cancer cells and
associated stromal cells directly by oncolysis or indir-
ectly by anti-angiogenesis, vascular-targeting and by-stander effect; and (2). They efficiently present/release
DAMPs and PAMPs (signal 0) and present TAAs (signal
1) to DCs in order to trigger a TAA-specific antitumor
immunity. However, OVs by themselves may not be
enough because the immunosuppressive TME often im-
pairs the functions of both innate and adaptive immune
cells. Therefore, investigators have designed a number of
combination strategies to overcome the TME and po-
tentiate the antitumor immunity initiated by the OVs.
We have discussed a variety of combination strategies
with OVs to boost the antitumor immunity and sustain
their cytotoxic activity against cancer in the TME. These
strategies are targeted at the stages of immunogenicity of
(dying) cancer cells, the process of antigen presentation,
the potency of immune cells, and the overall immuno-
logical status of the TME, the latter of which can be mod-
ulated via blockade of immune checkpoints, depletion of
immunosuppressive cells, and/or further activation of im-
mune effector cells by either active immunization, or/and
by adoptive T cell transfer. We envision that antitumor
immunity elicited by OVs properly armed or rationally
combined would kill not only residual cancer stem cells
and “differentiated” cancer cells in primary cancer and
metastases, but also maintain micrometastases in dormant
status. This is a key for treating metastatic cancer.
In phases I-II clinical trials, several OVs armed with ei-
ther GM-CSF or CD40L showed specific antitumor im-
munity, significant antitumor activity and clinical responses
in a significant fraction of cancer patients. T-VEC has dem-
onstrated efficacy in a phase III trial for melanoma patients
while Pexa-Vec has been tested in a phase IIb trial for pa-
tients with hepatocellular carcinoma. It is likely that one or
both of them may be approved by FDA in the near future.
Looking forward, this new class of therapeutic cancer vac-
cines is promising and more efforts should be invested in
both preclinical and clinical investigations.
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